Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Initiation
  • Markets
  • News
  • Price Target
  • Trading Ideas

Dianthus’ Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand – Analyst

By Vandana Singh
September 28, 3:33 PM
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.

AZN

Read More
1 minute read
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • News
  • Trading Ideas

Impact on BioMarin’s Sentiment: Voxzogo’s Triumph Clouded by Uncertainty

By Vandana Singh
September 28, 2:29 PM
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in 

ASND

Read More
1 minute read
  • Analyst Ratings
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Price Target
  • Trading Ideas
  • Upgrades

Bionomics’ Victory – Analysts Note Optimism Around Promising Prospects for PTSD Treatment

By Vandana Singh
September 28, 2:22 PM
Earlier today, Bionomics Limited (NASDAQ: BNOX) announced topline results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic 

BNOX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Two Trial Halts In A Row – Gilead Sciences Stops Late Stage COVID-19 Study

By Vandana Singh
September 28, 1:35 PM
Gilead Sciences Inc (NASDAQ: GILD) said it has 

GILD

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

Imunon Highlights Early Data From Lead Program In Ovarian Cancer

By Vandana Singh
September 28, 1:24 PM
Imunon Inc (NASDAQ: IMNN) announces interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in its Phase 1/2 OVATION 2 Study of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) for newly diagnosed with advanced epithelial ovarian, fallopian tube

IMNN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer

By Vandana Singh
September 28, 12:54 PM
BioLineRx Ltd (NASDAQ: BLRX) announced data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination trial of motixafortide and gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone, in first-line 

BLRX

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News

Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease

By Vandana Singh
September 28, 12:41 PM
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.

FOLD

Read More
1 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • Large Cap
  • News

Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs

By Vandana Singh
September 28, 10:19 AM
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation

AZN

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Government
  • Health Care
  • Movers
  • News
  • Penny Stocks

Why Is Vaccine Focused Gritstone bio Stock Trading Higher Today?

By Vandana Singh
September 28, 8:54 AM
Gritstone Bio Inc (NASDAQ: GRTS) received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study evaluating its self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets to 

GRTS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

Why Is Stress Disorder Focused Bionomics Stock Trading Higher Today?

By Vandana Singh
September 28, 8:24 AM
Bionomics Limited (NASDAQ: BNOX) announced topline results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic 

BNOX

Posts pagination

Previous 1 … 152 153 154 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service